DUBLIN–(BUSINESS WIRE)–The “Oral Thin Films Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering.
The oral thin films market studied is anticipated to register a CAGR of nearly 8.1%, during the forecast period.
Companies Mentioned
- Aquestive Therapeutics Inc.
- IntelGenx Corp.
- LTS Lohmann Therapie-Systeme AG
- Mylan Inc.
- NAL Pharma
- Novartis AG
- Solvay
- ZIM Laboratories Limited
- Sunovion Pharmaceuticals, Inc
- Cure Pharmaceutical
Key Market Trends
The Sublingual Film Segment Holds a Significant Share of the Market
Pharmaceutical scientists throughout the world are trying to explore thin films as a novel drug delivery tool. Thin films have been identified as an alternative approach to conventional dosage forms. The sublingual route is targeted for the delivery of drugs exhibiting high permeability across the mucosa and is utilized for the treatment of acute disorders. Systemic drug delivery is achieved by the diffusion of the active ingredients through the ventral surface of the tongue and the floor of the mouth.
Tailorable Sublingual films are also available in the market having characteristics including dissolution rates, adhesion, film thickness, material composition, taste-masking, and Active Pharmaceutical Ingredient absorption rates. Dissolution may be triggered for a specific biological fluid, pH, or other condition. Multi-layered product constructions were available for optimum bio-availability and stability.
Additionally, market players in this segment are continuously launching new products to gain a competitive edge. For instance, In February 2019, Mylan N.V. has launched Buprenorphine and Naloxone Sublingual Film, in the United States and in the same month of 2019, Dr. Reddy’s Laboratories Ltd also launched the generic version of the Indivior’s Suboxone Sublingual Film in the United States.
North America Dominates the Market
In the North American region, the United States accounted for the largest market share, as a major section of the population is approaching schizophrenia medication therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care, for early treatment capabilities, along with the involvement of the government in increasing healthcare expenditure. This is driving the growth of the market studied.
Moreover, new product launches and the presence of the key market players are anticipated to fuel the market growth over the forecast period. In November 2019, Aquestive Therapeutic’s Exservan Oral Film received early-action approval from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Target Diseases
4.2.2 Advantages Associated with the Thin Films
4.3 Market Restraints
4.3.1 Technical Limitations of Oral Thin Films
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product
5.2 By Disease Indication
5.3 By Distribution Channel
5.4 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/tu7nse
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900